Title |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, May 2013
|
DOI | 10.1186/1745-6215-14-143 |
Pubmed ID | |
Authors |
Menno R Germans, René Post, Bert A Coert, Gabriël JE Rinkel, W Peter Vandertop, Dagmar Verbaan |
Abstract |
A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm. The risk is highest within the first 6 hours after the initial hemorrhage. Securing the aneurysm within this timeframe is difficult owing to logistical delays. The rate of recurrent bleeding can also be reduced by ultra-early administration of antifibrinolytics, which probably improves functional outcome. The aim of this study is to investigate whether ultra-early and short-term administration of the antifibrinolytic agent tranexamic acid (TXA), as add-on to standard SAH management, leads to better functional outcome. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 17% |
Denmark | 1 | 17% |
Unknown | 4 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 67% |
Scientists | 1 | 17% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 1% |
Spain | 1 | <1% |
Unknown | 133 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 16% |
Student > Bachelor | 16 | 12% |
Student > Master | 14 | 10% |
Other | 13 | 10% |
Student > Ph. D. Student | 11 | 8% |
Other | 32 | 24% |
Unknown | 28 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 71 | 52% |
Neuroscience | 10 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Nursing and Health Professions | 3 | 2% |
Agricultural and Biological Sciences | 3 | 2% |
Other | 11 | 8% |
Unknown | 33 | 24% |